-
Vertex Plans to Seek Approval of VX-445 Triple Combo in US and Europe
Vertex Pharmaceuticals chose its VX-445 triple regimen to apply for regulatory approvals in the U.S. and Europe for the treatment of CF in those 12 and up. Read more about this choice here.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.